MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525933 | Name: Fenirofibrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fenirofibrate is a metabolite of Fenofibrate.

Chemical Structure

Fenirofibrate
Fenirofibrate
CAS#54419-31-7

Theoretical Analysis

MedKoo Cat#: 525933

Name: Fenirofibrate

CAS#: 54419-31-7

Chemical Formula: C17H17ClO4

Exact Mass: 320.0815

Molecular Weight: 320.77

Elemental Analysis: C, 63.66; H, 5.34; Cl, 11.05; O, 19.95

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Fenirofibrate; Fenirofibrato; Fenirofibrate, (+)-; LF-2151; LF2151; LF 2151
IUPAC/Chemical Name
2-[4-[(4-Chlorophenyl)-hydroxymethyl]phenoxy]-2-methylpropanoic acid
InChi Key
ASDCLYXOQCGHNT-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H17ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10,15,19H,1-2H3,(H,20,21)
SMILES Code
CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)O)C=C1)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 320.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Xu H, Han Y, Lou J, Zhang H, Zhao Y, Győrffy B, Li R. PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer. Oncotarget. 2017 May 13. doi: 10.18632/oncotarget.17846. [Epub ahead of print] PubMed PMID: 28562323. 2: Kim TK. Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate. Drug Res (Stuttg). 2017 May 30. doi: 10.1055/s-0043-109243. [Epub ahead of print] PubMed PMID: 28561239. 3: Du L, Ma Y, Liu M, Yan L, Tang H. Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo. Virol J. 2017 May 25;14(1):96. doi: 10.1186/s12985-017-0765-x. PubMed PMID: 28545573; PubMed Central PMCID: PMC5445479. 4: Müller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovasc Diabetol. 2017 May 25;16(1):70. doi: 10.1186/s12933-017-0552-4. PubMed PMID: 28545518; PubMed Central PMCID: PMC5445362. 5: Lin P, Lu JM, Wang YF, Gu W, Zhao RH, Yu J. Prevention Mechanism of 2,3,5,4'-Tetrahydroxy-stilbene-2-O-β-D-glucoside on Lipid Accumulation in Steatosis Hepatic L-02 Cell. Pharmacogn Mag. 2017 Apr-Jun;13(50):245-253. doi: 10.4103/0973-1296.204563. Epub 2017 Apr 18. PubMed PMID: 28539716; PubMed Central PMCID: PMC5421421. 6: Cecinato A, Romagnoli P, Perilli M, Balducci C. Pharmaceutical substances in ambient particulates: A preliminary assessment. Chemosphere. 2017 May 18;183:62-68. doi: 10.1016/j.chemosphere.2017.05.100. [Epub ahead of print] PubMed PMID: 28535462. 7: Ferrari R, Aguiar C, Alegria E, Bonadonna RC, Cosentino F, Elisaf M, Farnier M, Ferrières J, Filardi PP, Hancu N, Kayikcioglu M, Mello E Silva A, Millan J, Reiner Ž, Tokgozoglu L, Valensi P, Viigimaa M, Vrablik M, Zambon A, Zamorano JL, Catapano AL. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl. 2016 Apr 12;18(Suppl C):C2-C12. doi: 10.1093/eurheartj/suw009. PubMed PMID: 28533705; PubMed Central PMCID: PMC5421207. 8: Göke K, Bunjes H. Parameters influencing the course of passive drug loading into lipid nanoemulsions. Eur J Pharm Biopharm. 2017 May 18. pii: S0939-6411(17)30183-2. doi: 10.1016/j.ejpb.2017.05.009. [Epub ahead of print] PubMed PMID: 28529070. 9: Anabtawi A, Moriarty PM, Miles JM. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. Curr Cardiol Rep. 2017 Jul;19(7):62. doi: 10.1007/s11886-017-0872-8. Review. PubMed PMID: 28528456. 10: Suraweera D, Rahal H, Jimenez M, Viramontes M, Choi G, Saab S. Treatment of Primary Biliary Cholangitis Non-responders: A Systematic Review. Liver Int. 2017 May 18. doi: 10.1111/liv.13477. [Epub ahead of print] PubMed PMID: 28517369. 11: Croyal M, Kaabia Z, León L, Ramin-Mangata S, Baty T, Fall F, Billon-Crossouard S, Aguesse A, Hollstein T, Sullivan DR, Nobecourt E, Lambert G, Krempf M. Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD? Diabetes Metab. 2017 May 9. pii: S1262-3636(17)30074-5. doi: 10.1016/j.diabet.2017.04.003. [Epub ahead of print] PubMed PMID: 28499696. 12: Loh TY, Cohen PR. Ketoprofen-induced photoallergic dermatitis. Indian J Med Res. 2016 Dec;144(6):803-806. doi: 10.4103/ijmr.IJMR_626_16. Review. PubMed PMID: 28474616; PubMed Central PMCID: PMC5433272. 13: Kast RE, Hill QA, Wion D, Mellstedt H, Focosi D, Karpel-Massler G, Heiland T, Halatsch ME. Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Tumour Biol. 2017 May;39(5):1010428317699797. doi: 10.1177/1010428317699797. PubMed PMID: 28459367. 14: Dening TJ, Rao S, Thomas N, Prestidge CA. Montmorillonite-lipid hybrid carriers for ionizable and neutral poorly water-soluble drugs: Formulation, characterization and in vitro lipolysis studies. Int J Pharm. 2017 Apr 27;526(1-2):95-105. doi: 10.1016/j.ijpharm.2017.04.063. [Epub ahead of print] PubMed PMID: 28456653. 15: Huang YP, Chang NW. Proteomic analysis of oral cancer reveals new potential therapeutic targets involved in the Warburg effect. Clin Exp Pharmacol Physiol. 2017 Apr 28. doi: 10.1111/1440-1681.12774. [Epub ahead of print] PubMed PMID: 28453233. 16: Shinnakasu A, Yamamoto K, Kurano M, Arimura H, Arimura A, Kikuti A, Hashiguchi H, Deguti T, Nishio Y. The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes. J Atheroscler Thromb. 2017 Apr 27. doi: 10.5551/jat.39446. [Epub ahead of print] PubMed PMID: 28450679. 17: Roese E, Bunjes H. Drug release studies from lipid nanoparticles in physiological media by a new DSC method. J Control Release. 2017 Apr 24;256:92-100. doi: 10.1016/j.jconrel.2017.04.032. [Epub ahead of print] PubMed PMID: 28450207. 18: Nos D, Navarro J, Barría C, Solé M. Carboxylesterase activities in chondrichthyans of the western Mediterranean Sea. Mar Pollut Bull. 2017 Jun 15;119(1):332-335. doi: 10.1016/j.marpolbul.2017.04.021. Epub 2017 Apr 25. PubMed PMID: 28438337. 19: Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL. PubMed PMID: 28437620. 20: Ascaso JF; en nombre del Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis., Ferrari R; en nombre del Grupo Europeo de Expertos.. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. Clin Investig Arterioscler. 2017 Apr 19. pii: S0214-9168(16)30177-2. doi: 10.1016/j.arteri.2016.12.001. [Epub ahead of print] English, Spanish. PubMed PMID: 28433209.

View History

6-Bn-ATP

6-Bn-ATP